Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE Kids 2
PACTR202007786627403Phase 3Not yet recruiting
- Sponsor
- Global Blood Therapeutics
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Voxelotor with Placebo (2 arms). Primary endpoint: Change in transcranial Doppler time-averaged mean of the maximum velocity at Week 24. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202007786627403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007786627403.